Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Announces Phosphospecific Antibodies Production - Cellular phosphorylation is a reversible, covalent modification of a protein or lipid that results in the modification of the activity of the phosphorylated molecule by inducing small conformational changes within the molecule.1-2 - AnaSpec.com
AnaSpec Announces Phosphospecific Antibodies Production

 

PRZOOM - /newswire/ - Fremont, CA, United States, 2012/08/06 - Cellular phosphorylation is a reversible, covalent modification of a protein or lipid that results in the modification of the activity of the phosphorylated molecule by inducing small conformational changes within the molecule.1-2 - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Catalyzed by protein kinases, phosphate groups can be added via the transfer of the terminal phosphate from a phosphate donor, e.g. ATP to an amino acid residue, such as serine, threonine or tyrosine (Figure 1). The functions of phosphorylation, the most prevalent of post-translational modifications, include the alteration of the activity of a substrate, its subcellular localization, binding properties with other proteins.1-2 To better understand phosphorylation and its functional role, the generation and use of phosphospecific antibodies is crucial.

For raising antibodies against phosphopeptides there are 3 critical factors for success: (1) the stability of the phosphorylation, (2) the purity of the peptide and (3) post-development purification of the phosphospecific antibody. With documented experience in meeting all three factors, AnaSpec, EGT Group is a proven source for world-class phosphospecific antibody production.

With full manufacturing facilities located in Fremont, CA, AnaSpec (anaspec.com) is able to maintain ISO9001:2008 manufacturing processes and robust quality validation. Our peptide chemists routinely synthesize sequences containing single and multiple phosphoamino acids using technologies that are fine-tuned to produce high-yield, ultra-pure phosphopeptides. Antibodies generated are then substantiated to be phosphospecific.
AnaSpec offers both polyclonal and monoclonal antibody production services for the generation of phospho and non-phosphospecific antibodies. For polyclonal antibodies, researchers have a choice between two immunization protocols - the Speedy 28-day protocol (an example of results is shown in Figure 2) and the 70-day standard protocol. As a trusted provider to the global research community, we are experienced in fulfilling the most stringent demands for optimizing project success. As well, AnaSpec carries a wide selection of phosphospecific catalog antibodies such as the Anti-p53’s and Anti-TAU’s. Phosphospecific antibodies that are zebrafish reactive are also available.

References:
1. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: W H Freeman; 2002. Section 10.4, Covalent Modification Is a Means of Regulating Enzyme Activity.
2. Cohen, P. Proc R Soc Lond 234, 115 (1998). doi: 10.1098/rspb.1988.0040.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Announces Phosphospecific Antibodies Production

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate
Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen Completes Acquisition of ImCheck Therapeutics, Expanding Oncology Pipeline
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
Frost Radar™ Identifies Top Growth and Innovation Leaders in Pharmaceutical and Biotech Laboratory Information Management Systems
Ono Submits an Application for Approval of Cenobamate (ONO-2017), Antiseizure Medications in Japan
Viva Biotech Receives Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2005-2025 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today